on IKONISYS (EPA:ALIKO)
ALIKO Scientific concludes a $2 million deal
On September 21, 2026, ALIKO Scientific, the parent company of a group dedicated to oncology diagnostics, announced an amicable settlement in a dispute involving its American subsidiary. This agreement allows the subsidiary to receive $2 million. All legal proceedings have been closed, thus ending the litigation.
ALIKO Scientific, listed on Euronext Growth Paris, is recognized for its innovations in cancer diagnostics, combining cutting-edge technologies and strategic investments. The company continues to develop its activities through its international subsidiaries, particularly in Italy and the United States.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all IKONISYS news